{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:47Z","timestamp":1792892087430,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013749","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000}}],"reference-count":88,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["RIA2016V-1640-PREV_PKDL"],"award-info":[{"award-number":["RIA2016V-1640-PREV_PKDL"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224290"],"award-info":[{"award-number":["224290"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visceral leishmaniasis (VL) is the most severe form of leishmaniasis, with East Africa accounting for ~70% of global burden. It primarily affects malnourished children, young adults, and HIV co-infected individuals. Clinical outcomes range from asymptomatic to fatal, with relapse mostly linked to HIV co-infection, splenomegaly, high parasite load, poor immune responses, and elevated IgG1 concentration. In rodent VL models, systemic immune and metabolic abnormalities persist at the end of the drug treatment regime. However, the immune status of VL patients in East Africa at the end of treatment is not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/principal findings<\/jats:title>\n                    <jats:p>We conducted ImmStat@cure, a multicentre clinical study to assess clinical and immune profiles of VL patients at admission and end of treatment (EoT) in East African countries. Clinical, haematological and inflammatory markers data were collected from patients from Ethiopia, Kenya, Sudan and Uganda on both time points and from convenience controls at a single time point. By integrating clinical data with haematological and inflammation markers, we have shown that patient clinical and inflammatory profiles varied at admission and partially reverted to healthy range at EoT. Partial least squares determination and logistic regression showed that concentrations of inflammatory markers, including soluble TNF receptors and sCD40L, consistently changed between admission and EoT in all four countries, and were associated with increased odds of hepatomegaly and splenomegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/significance<\/jats:title>\n                    <jats:p>The recovery of haematological parameters, alongside a reduction in systemic inflammatory markers may be indicative of successful treatment of VL in East Africa. The biomarker dynamics suggest a partial resolution of inflammation and restoration of immune homeostasis during treatment. To confirm their predictive value, these markers should be evaluated in cohorts with a larger number of patients who experience treatment failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0013749","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:38:57Z","timestamp":1772217537000},"page":"e0013749","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic inflammatory markers of visceral leishmaniasis treatment response in East Africa"],"prefix":"10.1371","volume":"20","author":[{"given":"Ayenew","family":"Addisu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bayiyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o L.","family":"Reis Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Matano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brima M.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Biwott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnley","family":"Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ichugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew Jejaw","family":"Zeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Ayele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Obondo","family":"Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltahir A. G.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam M. H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I. B.","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Adiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J. N.","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat M.","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-4755","authenticated-orcid":true,"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Mbuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Olobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Immstat@Cure Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"pntd.0013749.ref001","year":"2024"},{"issue":"10151","key":"pntd.0013749.ref002","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"S Burza","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"pntd.0013749.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"pntd.0013749.ref004","unstructured":"World Health Organization. Regional Office for South-East Asia. Regional strategic framework for accelerating and sustaining elimination of kala-azar in the South-East Asia Region: 2022\u20132026. World Health Organization. Regional Office for South-East Asia. 2022."},{"issue":"5","key":"pntd.0013749.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00028-4","article-title":"Bangladesh eliminates visceral leishmaniasis","volume":"5","author":"N Nagi","year":"2024","journal-title":"Lancet Microbe"},{"issue":"4","key":"pntd.0013749.ref006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/inthealth\/ihaf013","article-title":"Kala-azar elimination in India: reflections on success and sustainability","volume":"17","author":"DK Pandey","year":"2025","journal-title":"Int Health"},{"key":"pntd.0013749.ref007","volume-title":"Strategic framework for the elimination of visceral leishmaniasis as a public health problem in eastern Africa 2023\u20132030: web annex: the Nairobi Declaration","year":"2024"},{"issue":"5","key":"pntd.0013749.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008319","article-title":"Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis","volume":"14","author":"C Abongomera","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0013749.ref009","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4269\/ajtmh.2007.76.909","article-title":"The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village","volume":"76","author":"C Bern","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0013749.ref010","doi-asserted-by":"crossref","first-page":"102229","DOI":"10.1016\/j.parint.2020.102229","article-title":"Prevalence and associated factors of asymptomatic leishmaniasis: a systematic review and meta-analysis","volume":"81","author":"SB Mannan","year":"2021","journal-title":"Parasitol Int"},{"issue":"7","key":"pntd.0013749.ref011","article-title":"Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis","volume":"8","author":"VS Belo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"14","key":"pntd.0013749.ref012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1286-4579(02)00027-8","article-title":"The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan","volume":"4","author":"B Bucheton","year":"2002","journal-title":"Microbes Infect"},{"issue":"5","key":"pntd.0013749.ref013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-3024.2009.01102.x","article-title":"Genetics and visceral leishmaniasis: of mice and man","volume":"31","author":"JM Blackwell","year":"2009","journal-title":"Parasite Immunol"},{"issue":"6","key":"pntd.0013749.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02068-22","article-title":"Parasite Genotype Is a Major Predictor of Mortality from Visceral Leishmaniasis","volume":"13","author":"CA Grace","year":"2022","journal-title":"mBio"},{"key":"pntd.0013749.ref015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00439-020-02130-w","article-title":"Human genetics of leishmania infections","volume":"139","author":"JM Blackwell","year":"2020","journal-title":"Hum Genet"},{"key":"pntd.0013749.ref016","article-title":"Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis","volume":"45","author":"M Fakiola","year":"2013","journal-title":"Nature genetics"},{"key":"pntd.0013749.ref017","doi-asserted-by":"crossref","first-page":"618766","DOI":"10.3389\/fvets.2021.618766","article-title":"Leishmaniasis Beyond East Africa","volume":"8","author":"CM Jones","year":"2021","journal-title":"Front Vet Sci"},{"issue":"5","key":"pntd.0013749.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197430","article-title":"Visceral leishmaniasis in selected communities of Hamar and Banna-Tsamai districts in Lower Omo Valley, South West Ethiopia: Sero-epidemological and Leishmanin Skin Test Surveys","volume":"13","author":"F Bekele","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"pntd.0013749.ref019","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5662\/wjm.v12.i4.305","article-title":"Prevalence of human leishmaniasis in Sudan: A systematic review and meta-analysis","volume":"12","author":"M Ahmed","year":"2022","journal-title":"World J Methodol"},{"issue":"9","key":"pntd.0013749.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003131","article-title":"Visceral leishmaniasis in Ethiopia: an evolving disease","volume":"8","author":"S Leta","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013749.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009204","article-title":"Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis","volume":"15","author":"P Dahal","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0013749.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007457","article-title":"\u201cIt\u2019s just a fever\u201d: Gender based barriers to care-seeking for visceral leishmaniasis in highly endemic districts of India: A qualitative study","volume":"13","author":"B Jayakumar","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013749.ref023","doi-asserted-by":"crossref","first-page":"20503121211036787","DOI":"10.1177\/20503121211036787","article-title":"Clinical and laboratory profiles of visceral leishmaniasis among adult patients admitted to Felege Hiwot Hospital, Bahir Dar, Ethiopia","volume":"9","author":"B Tarekegn","year":"2021","journal-title":"SAGE Open Med"},{"issue":"2","key":"pntd.0013749.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007132","article-title":"Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia","volume":"13","author":"E Diro","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013749.ref025","doi-asserted-by":"crossref","first-page":"100487","DOI":"10.1016\/j.xcrm.2021.100487","article-title":"Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV","volume":"3","author":"Y Takele","year":"2021","journal-title":"Cell Rep Med"},{"issue":"8","key":"pntd.0013749.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009713","article-title":"Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg\/kg\/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg\/kg\/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia","volume":"15","author":"A Tamiru","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013749.ref027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","article-title":"Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy","volume":"77","author":"Y Melaku","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pntd.0013749.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"A Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013749.ref029","doi-asserted-by":"crossref","first-page":"100317","DOI":"10.1016\/j.lansea.2023.100317","article-title":"Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review","volume":"22","author":"R Chhajed","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"pntd.0013749.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000705","article-title":"Visceral Leishmaniasis Relapse in Southern Sudan (1999\u20132007): A Retrospective Study of Risk Factors and Trends","volume":"4","author":"S Gorski","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013749.ref031","article-title":"Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) in Bihar, India","volume":"8","author":"S Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0013749.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100220","article-title":"Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia","volume":"9","author":"B Ostyn","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"pntd.0013749.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003273","article-title":"IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test","volume":"8","author":"T Bhattacharyya","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0013749.ref034","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/cid\/ciab124","article-title":"Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa","volume":"73","author":"L Verrest","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pntd.0013749.ref035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12688\/wellcomeopenres.14867.2","article-title":"Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis","volume":"3","author":"H Ashwin","year":"2019","journal-title":"Wellcome Open Res"},{"issue":"2","key":"pntd.0013749.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00679-22","article-title":"Tissue Specific Dual RNA-Seq Defines Host-Parasite Interplay in Murine Visceral Leishmaniasis Caused by Leishmania donovani and Leishmania infantum","volume":"10","author":"S Forrester","year":"2022","journal-title":"Microbiol Spectr"},{"key":"pntd.0013749.ref037","doi-asserted-by":"crossref","first-page":"198","DOI":"10.12688\/wellcomeopenres.15606.1","article-title":"Tissue-specific transcriptomic changes associated with AmBisome\u00ae treatment of BALB\/c mice with experimental visceral leishmaniasis","volume":"4","author":"S Forrester","year":"2019","journal-title":"Wellcome Open Res"},{"issue":"8","key":"pntd.0013749.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009632","article-title":"Antibody and cytokine levels in visceral leishmaniasis patients with varied parasitemia before, during, and after treatment in patients admitted to Arba Minch General Hospital, southern Ethiopia","volume":"15","author":"D Tadesse","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0013749.ref039","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1017\/S0031182024000751","article-title":"Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya","volume":"151","author":"N van Dijk","year":"2024","journal-title":"Parasitology"},{"key":"pntd.0013749.ref040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2172-15-16","article-title":"Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections","volume":"15","author":"E van den Bogaart","year":"2014","journal-title":"BMC Immunol"},{"key":"pntd.0013749.ref041","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.049","article-title":"Reconstructing Prehistoric African Population Structure","volume":"171","author":"P Skoglund","year":"2017","journal-title":"Cell"},{"issue":"5930","key":"pntd.0013749.ref042","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1126\/science.1172257","article-title":"The genetic structure and history of Africans and African Americans","volume":"324","author":"SA Tishkoff","year":"2009","journal-title":"Science"},{"issue":"18","key":"pntd.0013749.ref043","doi-asserted-by":"crossref","first-page":"10007","DOI":"10.3390\/ijms251810007","article-title":"Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19","volume":"25","author":"F Demeter","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pntd.0013749.ref044","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12979-024-00497-2","article-title":"Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART","volume":"22","author":"N Li","year":"2025","journal-title":"Immun Ageing"},{"issue":"1","key":"pntd.0013749.ref045","doi-asserted-by":"crossref","first-page":"15397","DOI":"10.1038\/s41598-025-99248-6","article-title":"Cytokine, chemokine, and acute-phase protein profiles in plasma as correlative biomarkers of clinical outcomes for patients with COVID-19","volume":"15","author":"SG Vanderkamp","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"pntd.0013749.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.1995.tb01618.x","article-title":"Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis","volume":"54","author":"A Diez-Ruiz","year":"1995","journal-title":"Eur J Haematol"},{"key":"pntd.0013749.ref047","doi-asserted-by":"crossref","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","article-title":"The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes","volume":"42","author":"JD Erusalimsky","year":"2021","journal-title":"Redox Biol"},{"issue":"11","key":"pntd.0013749.ref048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007980","article-title":"Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation","volume":"4","author":"TM Brusko","year":"2009","journal-title":"PLoS One"},{"issue":"10","key":"pntd.0013749.ref049","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"R Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"pntd.0013749.ref050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1615\/CritRevImmunol.v37.i2-6.100","article-title":"Functions of CD40 and Its Ligand, gp39 (CD40L)","volume":"37","author":"JD Laman","year":"2017","journal-title":"Crit Rev Immunol"},{"key":"pntd.0013749.ref051","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/1471-2334-13-331","article-title":"High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis","volume":"13","author":"FA de Oliveira","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"2","key":"pntd.0013749.ref052","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.90.2.775","article-title":"Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis","volume":"90","author":"JM Burns","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0013749.ref053","volume-title":"Control of the leishmaniases WHO TRS n\u00b0 949","year":"2010"},{"key":"pntd.0013749.ref054","year":"2025"},{"issue":"11","key":"pntd.0013749.ref055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: An R package for \u2019omics feature selection and multiple data integration","volume":"13","author":"F Rohart","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"pntd.0013749.ref056","author":"R Core Team","year":"2024"},{"key":"pntd.0013749.ref057","author":"T Konopka","year":"2023"},{"issue":"1","key":"pntd.0013749.ref058","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1469-0691.2000.00011.x","article-title":"Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis","volume":"6","author":"IM Medeiros","year":"2000","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"pntd.0013749.ref059","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.4049\/jimmunol.0903398","article-title":"sRAGE Induces Human Monocyte Survival and Differentiation","volume":"185","author":"Y Wang","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"pntd.0013749.ref060","doi-asserted-by":"crossref","first-page":"15659","DOI":"10.1096\/fj.202002136R","article-title":"The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways","volume":"34","author":"D Prantner","year":"2020","journal-title":"FASEB J"},{"key":"pntd.0013749.ref061","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"LA Rubin","year":"1985","journal-title":"J Immunol"},{"issue":"7","key":"pntd.0013749.ref062","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00134-020-06109-z","article-title":"Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial","volume":"46","author":"B Fran\u00e7ois","year":"2020","journal-title":"Intensive Care Med"},{"issue":"8","key":"pntd.0013749.ref063","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/s41423-021-00733-5","article-title":"sTREM-1 is a specific biomarker of TREM-1 pathway activation","volume":"18","author":"L Jolly","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"pntd.0013749.ref064","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1189\/jlb.0909602","article-title":"The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease","volume":"88","author":"N Karin","year":"2010","journal-title":"J Leukoc Biol"},{"key":"pntd.0013749.ref065","doi-asserted-by":"crossref","first-page":"920517","DOI":"10.1155\/2012\/920517","article-title":"Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response","volume":"2012","author":"P Kunes","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"3","key":"pntd.0013749.ref066","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.waojou.2024.100880","article-title":"Assessment of serum soluble CD40 ligand levels in patients with chronic rhinosinusitis","volume":"17","author":"Z Liu","year":"2024","journal-title":"World Allergy Organ J"},{"issue":"10","key":"pntd.0013749.ref067","article-title":"Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum Infection Reduces the Parasite Load in Macrophages","volume":"10","author":"FA de Oliveira","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"pntd.0013749.ref068","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/pathogens12070969","article-title":"From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis","volume":"12","author":"CHN Costa","year":"2023","journal-title":"Pathogens"},{"key":"pntd.0013749.ref069","article-title":"Clinico-hematological characteristics in patients with kala azar. A study from north-west India","volume":"43","author":"N Marwaha","year":"1991","journal-title":"Trop Geogr Med"},{"issue":"8","key":"pntd.0013749.ref070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007673","article-title":"Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India","volume":"13","author":"M Fakiola","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0013749.ref071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005123","article-title":"Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with Leishmania infantum","volume":"10","author":"LG Gardinassi","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0013749.ref072","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/infdis\/171.2.498","article-title":"Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis","volume":"171","author":"EE Zijlstra","year":"1995","journal-title":"J Infect Dis"},{"key":"pntd.0013749.ref073","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1164\/ajrccm.157.4.9709126","article-title":"Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis","volume":"157","author":"NP Juffermans","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"pntd.0013749.ref074","doi-asserted-by":"crossref","first-page":"155727","DOI":"10.1016\/j.cyto.2021.155727","article-title":"Soluble TNF receptors predict acute kidney injury and mortality in critically ill COVID-19 patients: A prospective observational study","volume":"149","author":"E Sancho Ferrando","year":"2022","journal-title":"Cytokine"},{"issue":"6","key":"pntd.0013749.ref075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ijpara.2007.09.013","article-title":"sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica","volume":"38","author":"MK Ellis","year":"2008","journal-title":"Int J Parasitol"},{"issue":"4","key":"pntd.0013749.ref076","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10096-013-1999-1","article-title":"Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment","volume":"33","author":"MS Duthie","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"pntd.0013749.ref077","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40249-020-00699-y","article-title":"Soluble IL-2R\u03b1 correlates with imbalances of Th1\/Th2 and Tc1\/Tc2 cells in patients with acute brucellosis","volume":"9","author":"H-L Sun","year":"2020","journal-title":"Infect Dis Poverty"},{"issue":"5","key":"pntd.0013749.ref078","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1006\/bbrc.2001.5090","article-title":"Identification of human ST2 protein in the sera of patients with autoimmune diseases","volume":"284","author":"K Kuroiwa","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"pntd.0013749.ref079","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","article-title":"Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation","volume":"164","author":"K Oshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pntd.0013749.ref080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"EO Weinberg","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"pntd.0013749.ref081","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s00134-004-2184-x","article-title":"Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma","volume":"30","author":"M Brunner","year":"2004","journal-title":"Intensive Care Med"},{"issue":"4","key":"pntd.0013749.ref082","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00134-010-1773-0","article-title":"Soluble ST2 plasma concentrations predict mortality in severe sepsis","volume":"36","author":"JJ Hoogerwerf","year":"2010","journal-title":"Intensive Care Med"},{"issue":"6","key":"pntd.0013749.ref083","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3343\/alm.2015.35.6.570","article-title":"Soluble ST2 has a prognostic role in patients with suspected sepsis","volume":"35","author":"M Hur","year":"2015","journal-title":"Ann Lab Med"},{"key":"pntd.0013749.ref084","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fcimb.2018.00428","article-title":"Serum Levels of Soluble CD40 Ligand and Neopterin in HIV Coinfected Asymptomatic and Symptomatic Visceral Leishmaniasis Patients","volume":"8","author":"W Adriaensen","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"pntd.0013749.ref085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4269\/ajtmh.1983.32.475","article-title":"Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis","volume":"32","author":"JD Chulay","year":"1983","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"pntd.0013749.ref086","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/cid\/cix607","article-title":"The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study","volume":"65","author":"C Abongomera","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pntd.0013749.ref087","doi-asserted-by":"crossref","first-page":"100583","DOI":"10.1016\/j.curtheres.2020.100583","article-title":"Multiple Relapses of Visceral Leishmaniasis in HIV Co-Infected Patients: A Case Series from Ethiopia","volume":"92","author":"R Mohammed","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"pntd.0013749.ref088","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12879-023-08009-1","article-title":"Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study","volume":"23","author":"LDLN Costa","year":"2023","journal-title":"BMC Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013749","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:54:24Z","timestamp":1772823264000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013749"}},"subtitle":[],"editor":[{"given":"Syamal","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013749","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}